Consistently, we show that DFMO and sulindac are able to remove both components of SOCs in CRC cells, thus, abolishing SOCE in CRC cells and providing a mechanism for increased chemoprevention efficiency of the combination vs. therapy with a single compound. The gene discussed is CISH; the disease is colorectal carcinoma.